Therapeutic Plasma Exchange Outcomes in Cairo University Hospitals: 6 Years Experience

Momtaz, Mohamed; Marzouk, Khaled; Shaker, Amr

doi:10.1111/1744-9987.12710

Cited by 6 publications

(5 citation statements)

References 32 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Generally, the number of treatment cycles was approximately five, consistent with descriptions that report a total fluid exchange divided five times in MG [24], GBS [22], and CIDP [3,25]. Jiao et al reported a slightly different range, 2-7 treatment cycles, in 29 patients with NMOSD [26], and Moser et al reported a wider range of cycles, 3-13, in 12 patients with AE [27].…”

Section: Discussionsupporting

confidence: 74%

“…For instance, Morgan et al clinically evaluated the improvement in patients with NMO, concluding that there was a moderate improvement in functional scales [32]. For MG, CIDP, and GBS, Momtaz et al focused on muscle strength, finding that of 31 patients with MG, 83.8% achieved a complete response; of 8 patients with CIDP, 87.5% achieved such a response; and of 39 patients with GBS, 51.3% responded in this way [25]. Titulaer et al described a cohort of 577 patients diagnosed with AE, of whom 461 received first-line therapies, including TPE: 97% maintained mRS scores of 0-2 during a year of follow-up [33].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Therapeutic Plasma Exchange as a Treatment for Autoimmune Neurological Disease

Nieto-Aristizábal

Vivas

Ruiz-Montaño

et al. 2020

Autoimmune Diseases

View full text Add to dashboard Cite

Introduction. Therapeutic plasma exchange (TPE) is commonly used as treatment of certain autoimmune neurological diseases (ANDs), and its main objective is the removal of pathogenic autoantibodies. Our aim was to describe the clinical profile and the experience with the usage of TPE in patients with ANDs at our institution. Methods. This is an observational retrospective study, including medical records of patients with diagnosis of ANDs who received TPE, between 2011 and 2018. Characteristics of TPE, such as number of cycles, type of replacement solution, and adverse effects, were evaluated. The modified Rankin Scale (mRS) was applied to measure the clinical response after the therapy. Results. 187 patients were included with the following diagnoses: myasthenia gravis (MG), n = 70 (37%); Guillain–Barré syndrome (GBS), n = 53 (28.3%), neuromyelitis optica spectrum disorders (NMOSD), n = 35 (18.7%); chronic inflammatory demyelinating polyneuropathy (CIDP), n = 23 (12.2%); and autoimmune encephalitis (AE), n = 6 (3.2%). The most used types of replacement solution were albumin (n = 131, 70%) and succinylated gelatin (n = 45, 24%). All patients received a median of five cycles (IQR 5-5). Hypotension and hydroelectrolytic disorders were the main complications. After TPE, 99 patients (52.9%) showed improvement in the mRS scores and a statistical significance (p<0.05) was seen between the admission score and after TPE for every diagnosis except for CIDP. Conclusion. TPE has an adequate safety profile, and improvement in functionality in treated patients reflects its effectiveness.

show abstract

Section: Discussionsupporting

confidence: 74%

Section: Discussionmentioning

confidence: 99%

Therapeutic Plasma Exchange as a Treatment for Autoimmune Neurological Disease

Nieto-Aristizábal

Vivas

Ruiz-Montaño

et al. 2020

Autoimmune Diseases

View full text Add to dashboard Cite

show abstract

“…This trend was the same in the research available on this subject by Kumar et al, in 2017, and Momtaz et al, in 2018. 8,16 The response to this treatment has also been positive, so clinicians prefer this mode of treatment for these illnesses worldwide.…”

Section: Discussionmentioning

confidence: 99%

Plasmapheresis in Neurological Disorders: Frequency and Type of Adverse Effects Associated with this Procedure in Atertiary Care Hospital in Pakistan

Kazmi

Alamgir²,

Hashmat³

et al. 2022

PAFMJ

View full text Add to dashboard Cite

Objective: To determine the frequency and type of adverse effects associated with plasmapheresis among the patients with neurological disorders at a tertiary care hospital in Pakistan. Study Design: Prospective longitudinal study. Place and Duration of Study: Pak Emirates Military Hospital, Rawalpindi Pakistan, from Jan to Jun 2019. Methodology: The sample population comprised 150 patients with various neurological disorders requiring plasmapheresis at a tertiary care hospital in Rawalpindi, Pakistan. The consultant neuro physician diagnosed the underlying disorder, and a management plan of plasmapheresis was given after the departmental meeting. The presence of adverse effects was observed during the session of plasmapheresis till 48 hours after the session. Results: Out of 150 patients with neurological illness undergoing plasmapheresis at our department, 18 (12%) developed one or more adverse effects due to the procedure, while 132 (88%) did not experience any adverse effects. The mean age of the patients was 30.2 ± 2.698 years. GB syndrome 61 (40.6%) was the commonest disease for which plasmapheresis was done. Allergic reaction 4 (2.6%) was the commonest side effect among the patients undergoing plasmapheresis, followed by abdominal pain 3 (2%). 146 (97.4%) patients were shifted toward, and 4 (2.6%) required intensive care unit admission after the procedure due to complications. Mortality due to this procedure was nil in the given period. Conclusion: Plasmapheresis is a relatively safe procedure for neurological illnesses with an immunological basis. Patients should be told about the common adverse effects they could face during the procedure especially allergic reactions and...

show abstract

“…Filtration results in almost twice the incidence of adverse reactions than centrifugation. 123,131 In addition, since there are fewer separators that can separate albumin, which has a similar molecular weight to the immunoglobulins present in autoimmune disorders, insufficient albumin supplementation during DFPP can easily lead to a loss of albumin and a decrease in blood volume. 132 Because DFPP can selectively remove…”

Section: Adverse Events Of Tpementioning

confidence: 99%

Therapeutic Plasma Exchange: For Cancer Patients

Yang

Shao

et al. 2022

CMAR

View full text Add to dashboard Cite

Therapeutic plasma exchange is used as a trial method for the treatment of cancer patients. Therapeutic plasma exchange uses in vitro technology to remove pathogenic factors in the plasma, returning the replacement and remaining components to the patient to facilitate cure. In the effort to explore new methods of cancer treatment, the introduction of therapeutic plasma exchange brings new hope for cancer treatment; however, the current evidence supporting therapeutic plasma exchange is controversial, and most of the evidence comes from observational studies, lacking large prospective randomized trials. Therefore, this review attempts to focus on the main indications of therapeutic plasma exchange for the treatment of tumors and their complications, including hematological tumors (multiple myeloma cast nephropathy and hyperviscosity syndrome), nervous system tumors (myasthenia gravis associated with thymoma, paraneoplastic neurological syndrome, Lambert-Eaton myasthenia syndrome, and anti-N-methyl-D-aspartate receptor encephalitis), overdose of chemotherapy drugs. In addition, the issues of side-effects and safety in the use of therapeutic plasma exchange are also discussed. However, well-designed prospective trials are needed to better define the role of therapeutic plasma exchange in cancer.

show abstract

Therapeutic Plasma Exchange Outcomes in Cairo University Hospitals: 6 Years Experience

Cited by 6 publications

References 32 publications

Therapeutic Plasma Exchange as a Treatment for Autoimmune Neurological Disease

Therapeutic Plasma Exchange as a Treatment for Autoimmune Neurological Disease

Plasmapheresis in Neurological Disorders: Frequency and Type of Adverse Effects Associated with this Procedure in Atertiary Care Hospital in Pakistan

Therapeutic Plasma Exchange: For Cancer Patients

Contact Info

Product

Resources

About